TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21334713

Group type: EXPERIMENTAL
Intervention: Overexpression of Forkhead Box M1 transcription factor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overexpression of nuclear factor-κB
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both Forkhead Box M1 transcription factor and nuclear factor-κB
Number of subjects: 0
Study: 19615313

Group type: EXPERIMENTAL
Intervention: Feitai Capsule
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 62
Study: 16534473

Group type: EXPERIMENTAL
Intervention: Cysporin
Number of subjects: 33
Study: 12720535

Group type: EXPERIMENTAL
Intervention: Cyclical etidronate therapy in conjunction with anti-rheumatic therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Anti-rheumatic therapy alone (without etidronate)
Number of subjects: 40
Study: 11114494

Group type: EXPERIMENTAL
Intervention: 20 mg buspirone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9085299

Group type: EXPERIMENTAL
Intervention: Single burst stimuli (8 mA)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Repeated burst stimuli (5 stimuli at 2 Hz)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Continuous burst stimuli (4 Hz for 30, 60, 90, and 120 s)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Repeated burst stimuli
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Single burst stimuli
Number of subjects: 9
Study: 8408474

Group type: EXPERIMENTAL
Intervention: Insulin + C-peptide
Number of subjects: 18

Group type: COMPARATOR
Intervention: Insulin only
Number of subjects: 18
Study: 3513531

Group type: EXPERIMENTAL
Intervention: 1 mg guanfacine daily at bedtime for 8 weeks
Number of subjects: 68

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 68
Study: 29195188

Group type: EXPERIMENTAL
Intervention: Individual Cognitive Behavioral Therapy (ICBT)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioral Therapy (GCBT)
Number of subjects: 139
Study: 28664389

Group type: EXPERIMENTAL
Intervention: Laser therapy (HPLT 970 ± 15 nm, 3.2 W (50%), 35-6000 Hz, 240 s for four consecutive days, once a day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo group (sham treatment)
Number of subjects: 16
Study: 25252696

Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control (uninflated cuffs)
Number of subjects: 180
Study: 24601174

Group type: EXPERIMENTAL
Intervention: DPP-4 inhibitors (sitagliptin) in combination with metformin
Number of subjects: 18
Study: 21227538

Group type: EXPERIMENTAL
Intervention: Self-management education intervention (including a self-management workbook, behavioral contract, inhaler training, and telephone reinforcements)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Control group (instruction from an asthma knowledge test, peak flowmeter training, and asthma brochures)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 296
Study: 18296958

Group type: EXPERIMENTAL
Intervention: Free-form strength group (FF n = 10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fixed form strength group (FX n = 10)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (C n = 10)
Number of subjects: 30
Study: 17003353

Group type: EXPERIMENTAL
Intervention: 600 IU of vitamin E (alpha‐tocopherol)
Number of subjects: 38716

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38716
Study: 12730857

Group type: EXPERIMENTAL
Intervention: Y-27632 (Rho kinase inhibitor)
Number of subjects: 0
Study: 11265390

Group type: EXPERIMENTAL
Intervention: Cochlear function estimation by otoacoustic emission in children treated with cytostatic drugs for leukemia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group of healthy children who have never suffered from ear diseases and have never used ototoxic drugs
Number of subjects: 0
Study: 8970026

Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 102

Group type: COMPARATOR
Intervention: Ketorolac
Number of subjects: 102
Study: 1335217

Group type: EXPERIMENTAL
Intervention: Buspirone (45 to 60 mg/day)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 3882525

Group type: EXPERIMENTAL
Intervention: 75 mg pirenzepine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 150 mg pirenzepine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29920688

Group type: EXPERIMENTAL
Intervention: Modified Constraint-Induced Movement Therapy (mCIMT)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 19
Study: 27436230

Group type: EXPERIMENTAL
Intervention: 250mg d‐cycloserine
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 25609562

Group type: EXPERIMENTAL
Intervention: Fast eating (5 min)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Regular eating (15 min)
Number of subjects: 9
Study: 24222526

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural treatment (CBT) programme supplemented with culturally sensitive aspects (CsCBT)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Culturally sensitive exercise therapy (CsET)
Number of subjects: 116
Study: 20560907

Group type: EXPERIMENTAL
Intervention: Synbiotics (Bifidobacterium breve M-16V and galacto/fructooligosaccharide mixture)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (same formula without synbiotics)
Number of subjects: 90
Study: 18498809

Group type: EXPERIMENTAL
Intervention: On-pump CABG
Number of subjects: 22

Group type: COMPARATOR
Intervention: Off-pump CABG
Number of subjects: 22
Study: 17293731

Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bupropion 150 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 0
Study: 15327018

Group type: EXPERIMENTAL
Intervention: Low-risk individuals for fasting venous plasma glucose (f‐vPG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-risk individuals for fasting venous plasma glucose (f‐vPG)
Number of subjects: 0
Study: 11731898

Group type: EXPERIMENTAL
Intervention: Nonmechanical trephination (excimer laser, 193-nm, 1.5 x 1.5 mm spot mode, 16-24 mJ/pulse, 25/s)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Mechanical trephination (motor trephine)
Number of subjects: 179
Study: 9142587

Group type: EXPERIMENTAL
Intervention: Endoscopically inserted intratracheal oxygen (eITO) catheter
Number of subjects: 0
Study: 7910322

Group type: EXPERIMENTAL
Intervention: Biosynthetic growth hormone (GH) at 4 IU per m2 per day
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Biosynthetic growth hormone (GH) at 8 IU per m2 per day
Number of subjects: 18

Group type: COMPARATOR
Intervention: Matched non-GH-treated controls
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: GH-treated patients
Number of subjects: 18

Group type: COMPARATOR
Intervention: Non-GH-treated controls
Number of subjects: 18
Study: 3349549

Group type: EXPERIMENTAL
Intervention: 150 ml coffee (Group 1)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 150 ml orange juice (Group 2)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Overnight fast (Group 3)
Number of subjects: 300
Study: 31577694

Group type: EXPERIMENTAL
Intervention: Coauthorship network analysis
Number of subjects: 2176

Group type: EXPERIMENTAL
Intervention: Influence metrics
Number of subjects: 2176

Group type: EXPERIMENTAL
Intervention: Geographical distribution of trialists
Number of subjects: 2176
Study: 30496409

Group type: EXPERIMENTAL
Intervention: Educational program with spouse's participation
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Educational program without spouse's participation
Number of subjects: 128

Group type: COMPARATOR
Intervention: Routine prenatal care (Control)
Number of subjects: 128
Study: 27577562

Group type: EXPERIMENTAL
Intervention: Mentalization-based treatment (MBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Structured clinical management (control)
Number of subjects: 0
Study: 24367124

Group type: EXPERIMENTAL
Intervention: 12-month collaborative care program involving antidepressants and psychotherapy
Number of subjects: 235

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 235
Study: 22452558

Group type: EXPERIMENTAL
Intervention: High confidence error condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low confidence correct condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High confidence wrong answer condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low confidence wrong answer condition
Number of subjects: 0
Study: 20473196

Group type: EXPERIMENTAL
Intervention: Patient mailings including a tailored letter, educational brochure, and fecal occult blood test kit at baseline and 6 months follow-up
Number of subjects: 21860

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 21860
Study: 18670227

Group type: EXPERIMENTAL
Intervention: Combined microfinance and training intervention
Number of subjects: 0
Study: 16162048

Group type: EXPERIMENTAL
Intervention: High incentive to cheat with high likelihood of getting caught
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low incentive to cheat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spontaneous counterfactual thought
Number of subjects: 0
Study: 14748464

Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg iv 30 min prior to cisplatin, followed by 8 mg orally for 24 h)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Metoclopramide (20 mg iv 30 min prior to cisplatin, followed by 20 mg orally for 24 h)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Dexamethasone + Ondansetron
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Dexamethasone + Metoclopramide
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 137

Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 137
Study: 10648376

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 81
Study: 8873834

Group type: EXPERIMENTAL
Intervention: Parenteral sulbactam-ampicillin (1.5 g, q.i.d.)
Number of subjects: 74
Study: 1954180

Group type: EXPERIMENTAL
Intervention: Chemotherapy in patients with more than 10% positive NSE cells
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Chemotherapy in patients with Chromogranin A
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: NSE-positive cells
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Chr A-positive cells
Number of subjects: 114
Study: 6831946

Group type: EXPERIMENTAL
Intervention: Phentolamine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Albuterol (salbutamol)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combination of phentolamine and albuterol
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Albuterol alone
Number of subjects: 15
Study: 31044354

Group type: EXPERIMENTAL
Intervention: School-based environmental interventions modeled from successful home-based interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: School-based interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ADA policy and Section 504 of the Rehabilitation Act
Number of subjects: 0
Study: 30075513

Group type: EXPERIMENTAL
Intervention: Ramosetron 0.6 mg added to 2-day intravenous patient-controlled analgesia (IV-PCA)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Ramosetron 1.2 mg added to 2-day intravenous patient-controlled analgesia (IV-PCA)
Number of subjects: 73

Group type: COMPARATOR
Intervention: No prophylactic ramosetron (Group C)
Number of subjects: 73
Study: 26597598

Group type: EXPERIMENTAL
Intervention: Vitamin C and E supplementation
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo-supplementation
Number of subjects: 57
Study: 1360145

Group type: EXPERIMENTAL
Intervention: Aerosolized pentamidine once a month
Number of subjects: 215

Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole 480 mg once a day
Number of subjects: 215

Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole 960 mg once a day
Number of subjects: 215

Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (both dosages)
Number of subjects: 215
Study: 22075088

Group type: EXPERIMENTAL
Intervention: Standard multi-dose hepatitis B vaccine schedule (0, 1, and 6 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Accelerated hepatitis B vaccine schedule (0, 1, and 2 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants aged 40 years or older
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants injecting drugs more than once a day
Number of subjects: 0
Study: 20345356

Group type: EXPERIMENTAL
Intervention: Skin traction with 2 kg of weights
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Skin traction without weights
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Pillow placement under the affected limb
Number of subjects: 108
Study: 17912568

Group type: EXPERIMENTAL
Intervention: DHA + ARA, soy‐based formula supplemented with at least 17 mg DHA/100 kcal and 34 mg ARA/100 kcal
Number of subjects: 244

Group type: COMPARATOR
Intervention: Control, soy‐based formula without supplementation
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: DHA + ARA, soy‐based formula supplemented with DHA and ARA
Number of subjects: 244
Study: 15784201

Group type: EXPERIMENTAL
Intervention: Sleep-restricted condition
Number of subjects: 22

Group type: COMPARATOR
Intervention: Non-restricted sleep condition
Number of subjects: 22
Study: 12456069

Group type: EXPERIMENTAL
Intervention: Cerebrolysin (Cere)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 15512377

Group type: EXPERIMENTAL
Intervention: sultrin (sulphathiazole 3.42%, sulphacetamide 2.86%, sulphabenzamide 3.7%) pessaries: one pessary twice daily for 5 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 100
Study: 8743520

Group type: EXPERIMENTAL
Intervention: Hypertensive NIDDM patients
Number of subjects: 146

Group type: COMPARATOR
Intervention: Normotensive NIDDM patients
Number of subjects: 146
Study: 1662266

Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg per day for 3 weeks)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 2982715

Group type: EXPERIMENTAL
Intervention: Mesotheliomas
Number of subjects: 30

Group type: COMPARATOR
Intervention: Adenocarcinomas of the lung
Number of subjects: 30

Group type: COMPARATOR
Intervention: Adenocarcinomas of the breast
Number of subjects: 30
Study: 31266486

Group type: EXPERIMENTAL
Intervention: Pragmatic randomized clinical trials (PCTs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modifications in study designs for PCTs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified informed consent procedures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified regulatory and oversight procedures
Number of subjects: 0
Study: 29760286

Group type: EXPERIMENTAL
Intervention: FemoSeal Vascular Closure Device (VCD)
Number of subjects: 3018

Group type: COMPARATOR
Intervention: Manual Compression
Number of subjects: 3018

Group type: EXPERIMENTAL
Intervention: FemoSeal VCD
Number of subjects: 3018
Study: 27052530

Group type: EXPERIMENTAL
Intervention: Dairy diet (3 servings/d of dairy: 375 mL 1% milk-fat milk, 175 g 1.5% MF yogurt, and 30 g of 34% MF cheese)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Dairy diet
Number of subjects: 101

Group type: COMPARATOR
Intervention: Energy-matched control products (juice, cashews, and cookies)
Number of subjects: 101
Study: 25204404

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate 1,000 mg/day
Number of subjects: 359

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 359
Study: 22739534

Group type: EXPERIMENTAL
Intervention: L-arginine buffered with citric acid (ARG.CITR)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: L-arginine buffered with HCl (ARG.HCl)
Number of subjects: 23
Study: 21057255

Group type: EXPERIMENTAL
Intervention: Family-based pediatric obesity program (treatment group)
Number of subjects: 155
Study: 20966444

Group type: EXPERIMENTAL
Intervention: Propofol (total IV anesthesia)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Desflurane anesthesia
Number of subjects: 134
Study: 16106024

Group type: EXPERIMENTAL
Intervention: Screening mammography
Number of subjects: 62000

Group type: COMPARATOR
Intervention: Interval cancers
Number of subjects: 62000

Group type: COMPARATOR
Intervention: Control groups (non-screened)
Number of subjects: 62000
Study: 11891487

Group type: EXPERIMENTAL
Intervention: Trillium-coated oxygenator
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard oxygenator
Number of subjects: 25
Study: 9838911

Group type: EXPERIMENTAL
Intervention: FK352
Number of subjects: 0

Group type: COMPARATOR
Intervention: mannitol
Number of subjects: 0
Study: 8028406

Group type: EXPERIMENTAL
Intervention: Perceived Health Index derived from health status measures
Number of subjects: 1862

Group type: EXPERIMENTAL
Intervention: Domain-specific health status scales
Number of subjects: 1862

Group type: EXPERIMENTAL
Intervention: Lowest quartile of Perceived Health Index scores
Number of subjects: 1862

Group type: EXPERIMENTAL
Intervention: Modified MOS health status scales included in the HIV-PARSE
Number of subjects: 1862
Study: 2732141

Group type: EXPERIMENTAL
Intervention: FCE 22101 (500 mg, 1000 mg, 750 mg, 1500 mg, 2000 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: FCE 22101 (1000 mg) with probenecid
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: FCE 22101 (1000 mg) without probenecid
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: FCE 22101 (1000 mg) via im injection
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: FCE 22101 (continuous infusion at 280 mg/h)
Number of subjects: 12
Study: 30241001

Group type: EXPERIMENTAL
Intervention: Buparlisib plus fulvestrant (100 mg/day buparlisib continuously in 28-day cycles; 500 mg fulvestrant on cycle 1 day 15 and day 1 of subsequent cycles)
Number of subjects: 1147

Group type: COMPARATOR
Intervention: Placebo plus fulvestrant (placebo continuously in 28-day cycles; 500 mg fulvestrant on cycle 1 day 15 and day 1 of subsequent cycles)
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: Buparlisib plus fulvestrant
Number of subjects: 1147

Group type: COMPARATOR
Intervention: Placebo plus fulvestrant
Number of subjects: 1147
Study: 28511195

Group type: EXPERIMENTAL
Intervention: No motor function assessment
Number of subjects: 1359

Group type: COMPARATOR
Intervention: Motor function assessment
Number of subjects: 1359
Study: 26149444

Group type: EXPERIMENTAL
Intervention: Stepped-care intervention package for depression, delivered by trained primary health care workers, including psychological interventions and medication based on severity and response.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 0
Study: 23806873

Group type: EXPERIMENTAL
Intervention: Soft Touch (slow brush stroke)
Number of subjects: 25
Study: 20563663

Group type: EXPERIMENTAL
Intervention: Vertical‐banded gastroplasty (VBG)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Laparoscopic adjustable gastric banding (LAGB)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both procedures (VBG and LAGB)
Number of subjects: 100
Study: 17845738

Group type: EXPERIMENTAL
Intervention: Brief group psychological intervention (PG) - three 90 minute cognitive behavioural sessions supported by an Information Booklet.
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Social discussion group (SDG) - received the same Information Booklet and participated in non-structured social discussion sessions.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Information Booklet group (IBG) - provided only with educational material.
Number of subjects: 90
Study: 17241576

Group type: EXPERIMENTAL
Intervention: Efalizumab (1 mg/kg for 12 weeks)
Number of subjects: 3500

Group type: EXPERIMENTAL
Intervention: Efalizumab (continuation at week 24)
Number of subjects: 3500

Group type: EXPERIMENTAL
Intervention: Efalizumab (36 months continuous treatment)
Number of subjects: 3500
Study: 14675308

Group type: EXPERIMENTAL
Intervention: Carboplatin and paclitaxel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cisplatin and paclitaxel
Number of subjects: 0
Study: 10953853

Group type: EXPERIMENTAL
Intervention: Intensive control with metformin
Number of subjects: 2

Group type: COMPARATOR
Intervention: Conventional glycaemic control
Number of subjects: 2
Study: 8866384

Group type: EXPERIMENTAL
Intervention: Ampicillin/sulbactam (2.0 g ampicillin + 1.0 g sulbactam every six hours)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Clindamycin/gentamicin (900 mg clindamycin + 1.5 mg/kg gentamicin every eight hours)
Number of subjects: 129
Study: 1727614

Group type: EXPERIMENTAL
Intervention: Prednisone and short-term oral cyclophosphamide
Number of subjects: 86
Study: 6373007

Group type: EXPERIMENTAL
Intervention: Hydrocortisone valerate 0.2% ointment
Number of subjects: 485
Study: 30415934

Group type: EXPERIMENTAL
Intervention: Early initiation of direct oral anticoagulants (DOACs) within 3-5 days after ischaemic stroke.
Number of subjects: 9000

Group type: EXPERIMENTAL
Intervention: Later initiation of direct oral anticoagulants (DOACs) after >7 days or >14 days post-stroke.
Number of subjects: 9000
Study: 25877236

Group type: EXPERIMENTAL
Intervention: Alcohol intoxication (mean BAC ≈ .08%)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo control (mean BAC ≈ .00%)
Number of subjects: 62
Study: 24830741

Group type: EXPERIMENTAL
Intervention: E-cigarette
Number of subjects: 41

Group type: COMPARATOR
Intervention: Nicotine inhaler
Number of subjects: 41
Study: 21450377

Group type: EXPERIMENTAL
Intervention: Online testing as an assistant tool
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control group 1
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control group 2
Number of subjects: 146
Study: 20363909

Group type: EXPERIMENTAL
Intervention: Positive affect with accessible egalitarian response tendencies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Positive affect without accessible egalitarian response tendencies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative affect
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positive affect with counterstereotypic thoughts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative affect with counterstereotypic thoughts
Number of subjects: 0